Šalis: Kanada
kalba: anglų
Šaltinis: Health Canada
CALCIUM CHLORIDE
PFIZER CANADA ULC
B05XA07
CALCIUM CHLORIDE
100MG
SOLUTION
CALCIUM CHLORIDE 100MG
INTRAVENOUS
10ML
Ethical
REPLACEMENT PREPARATIONS
Active ingredient group (AIG) number: 0108565001; AHFS:
APPROVED
2017-09-01
_Calcium Chloride Injection USP _ _Page 1 of 16_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION CALCIUM CHLORIDE INJECTION USP 100 mg/mL (27 mg [0.7 mmol or 1.4 mEq] Ca ++ /mL) 10% Hypertonic solution for intravenous injection Calcium Replenisher Pfizer Canada ULC 17300 Trans-Canada Highway Kirkland, Québec H9J 2M5 Date of Initial Authorization: December 31, 1981 Date of Revision: August 25, 2022 Submission Control Number: 262054 _ _ _Calcium Chloride Injection USP _ _Page 2 of 16_ RECENT MAJOR LABEL CHANGES CONTRAINDICATIONS (2) 08/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION................................................................................. 4 4.1 Dosing Considerations ....................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment..................................................... 4 4.4 Administration................................................................................................... 5 4.5 Missed Dose ...................................................................................................... 5 5 OVERDOSAGE ............................................................................................................. 5 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .................. Perskaitykite visą dokumentą